Receptor-mediated uptake of low-density lipoprotein by B16 melanoma cells in vitro and in vivo in mice

British Journal of Cancer

Volumn 74, Issue 4, 1996, Pages 525-532

  Versluis, A J ^a   Van Geel, P J ^b   Oppelaar, H ^b   Van Berkel, T J C ^a   Bijsterbosch, M K ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

B16 murine melanoma; Drug carrier; Low density lipoprotein; Low density lipoprotein receptor; Tumour therapy

Indexed keywords

AMMONIUM CHLORIDE; CELLOBIOSE; CHLOROQUINE; CHOLESTEROL; DRUG CARRIER; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; TYRAMINE;

ADRENAL GLAND; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER THERAPY; CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; ISOTOPE LABELING; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER; LYSOSOME; MALE; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; SPLEEN; TISSUE LEVEL;

EID: 0029782318     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.396     Document Type: Article

References (40)

1. ANGELIN B, RAVIOLA CA, INNERERITY TL AND MAHLEY RW. (1983). Regulation of hepatic lipoprotein receptors in the dog; rapid regulation of apolipoprotein B,E receptors, but not of apolipoprotein E receptors, by intestinal lipoproteins and bile acids. J. Clin. Invest., 71, 816 - 831.
2. BILHEIMER DW, EISENBERG S AND LEVY RI. (1972). The metabolism of very low density lipoproteins. I: Preliminary in vitro and in vivo observations. Biochim. Biophys. Acta, 280, 212 - 221.
3. BROWN MS AND GOLDSTEIN JL. (1975). Regulation of the activity of the low density lipoprotein receptor in human fibroblasts. Cell, 6, 307 - 316.
4. COUNSELL RE AND POHLAND RC. (1982). Lipoproteins as potential site-specific delivery systems for diagnostic and therapeutic agents. J. Med. Chem., 25, 1115 - 1120.
5. DIETSCHY JM, TURLEY SD AND SPADY DK. (1993). Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res., 34, 1637 - 1659.
6. FAN D, BUCANA CD, O'BRIAN CA, ZWELLING LA, SEID C AND FIDLER IJ. (1990). Enhancement of murine tumor cell sensitivity to adriamycin by presentation of the drug in phosphatidylcholine phosphatidylserine liposomes. Cancer Res., 50, 3619 - 3626.
7. FIRESTONE RA. (1994). Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjugate Chem., 5, 105 - 113.
8. FIRESTONE RA, PISANO JM, FALCK JR, MCPHAUL MM AND KRIEGER M. (1984). Selective delivery of cytotoxic compounds to cells by the LDL pathway. J. Med. Chem., 27, 1037 - 1043.
9. GOLDSTEIN JL AND BROWN MS. (1977). The low-density lipoprotein pathway and its relation to atherosclerosis. Annu. Rev. Biochem., 46, 897 - 930.
10. HABEEB AFSA. (1966). Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal. Biochem., 14, 328 - 336.
11. HAVEKES LM, SCHOUTEN D, DE WIT ECM, COHEN LH, GRIFFIOEN M, VAN HINSBERGH WM AND PRINCEN HMG. (1986). Stimulation of the LDL receptor activity in the human hepatoma cell line Hep G2 by high-density serum fractions. Biochim. Biophys. Acta, 875, 236 - 246.
12. HAY RV, FLEMING RM, RYAN JW, WILLIAMS KA, STARK VJ, LATHROP KA AND HARPER PV. (1991). Nuclear Imaging analysis of human low-density lipoprotein biodistribution in rabbits and monkeys. J. Nucl. Med., 32, 1239 - 1245.
13. HYNDS SA, WELSH J, STEWART JM, JACK A, SOUKOP M, MCARDLE CS, CALMAN KC, PACKARD CJ AND SHEPHERD J (1984). Low-density lipoprotein metabolism in mice with soft tissue tumours. Biochim. Biophys. Acta, 795, 589 - 595.
14. ISAACSOHN JL, LEES AM, LEES RS, STRAUSS HW, BARLAIKOVACH M AND MOORE TJ. (1986). Adrenal imaging with technetium-99m-labelled low density lipoproteins. Metabolism, 35, 364 - 366.
15. KAMPS JAAM, KUIPER J, KRUIJT JK AND VAN BERKEL ThJC. (1991). Complete down regulation of low density lipoprotein receptor activity in human liver parenchumal cells by β-very low density lipoprotein. FEBS Lett., 287, 34 - 38.
16. KLEINHERENBRINK-STINS MF, VAN DER BOOM J, BAKKEREN HF, ROHOLL PJM, BROUWER A, VAN BERKEL ThJC AND KNOOK DL. (1990). Light- and immunoelectron microscopic visualization of in vivo endocytosis of low density lipoprotein by hepatocytes and Kupffer cells in rat liver. Lab. Invest., 63, 73 - 86.
17. KNOTT TJ, PEASE RJ, POWELL LM, WALLIS SC, RALL SC, INNERARITY TL, BLACKHART B, TAYLOR WH, MARCEL Y, MILNE R, JOHNSON D, FULLER M, LUSIS AJ, MCCARTHY BJ, MAHLEY RM, LEVY WILSON B AND SCOTT J. (1986). Complete protein sequence and identification of structural domains of human apolipoprotein B. Nature, 323, 734 - 738.
18. LESTRAVEL-DELATTRE S, MARTIN-NIZARD F, CLAVEY V, TESTARD P, FAVRE G, DOUALIN G, SQALLI HOUSSAINI H, BARD J-M, DURIEZ P, DELBART C, SOULA G, LESIEUR D, LESIEUR I, CAZIN J-C, CAZIN M AND FRUCHART J-C. (1992). Low-density lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells. Cancer Res., 52, 3629-3635.
19. LOMBARDI P, NORATA G, MAGGI FM, CANTI G, FRANCO P, NICOLIN A AND CATAPANA AL. (1989). Assimilation of LDL by experimental tumours in mice. Biochim. Biophys. Acta, 1003, 301 - 306.
20. LOWRY OH, ROSEBROUGH NJ, FARR AL AND RANDALL RJ. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem., 93, 265-275.
21. LUNDBERG BB. (1993). Evaluation of methods for complexing prednimustine to low density lipoprotein. Int. J. Pharmaceut., 99, 275 - 283.
22. MAHLEY RW, WEISGRABER KH, MELCHIOR GW, INNERARITY TL AND HOLCOMBE KS. (1980). Inhibition of receptor-mediated clearance of lysine and arginine-modified lipoproteins from the plasma of rats and monkeys. Proc. Natl Acad. Sci. USA, 77, 225-229.
23. MOERLEIN SM, DALAL KB, EBBE SN, YANO Y AND BUDINGER TF. (1988). Residualizing and non-residualizing analogues of low-density lipoprotein as iodine-123 radiopharmaceuticals for imaging LDL catabolism. Nucl. Med. Biol., 15, 141 - 149.
24. MOSLEY ST, GOLDSTEIN JL, BROWN MS, FALCK JR AND ANDERSON RGW. (1981). Targeted killing of cultured cells by receptor-dependent photosensitization. Proc. Natl Acad. Sci. USA, 78, 5717 - 5721.
25. NORATA G, CANTI G, RICCI L, NICOLIN, A, TREZZI E AND CATAPANO AL. (1984). In vivo assimilation of low density lipoproteins by a fibrosarcoma tumour line in mice. Cancer Lett., 25, 203 - 208.
26. PITTMAN RC, CAREW TE, GLASS CK, GREEN SR, TAYLOR CA AND ATTIE AD. (1983). A radioiodinated, intracellularly trapped ligand for determining the sites of plasma protein degradation in vivo. Biochem. J., 212, 791-800.
27. 99mTc-labelled LDL in B16-melanoma-bearing mice. Visualization of a preferential uptake by the tumor. Int. J. Cancer, 54, 411-417.
28. REDGRAVE TG, ROBERTS DCK AND WEST CE. (1975). Separation of plasma lipoproteins by density gradient ultracentrifugation. Anal. Biochem., 65, 42 - 49.
29. SALTER AM, BUGAUT M, SAXTON J, FISHER SC AND BRINDLEY DN. (1987). Effects of preincubation of primary monolayer cultures of rat hepatocytes with low- and high-density lipoproteins on the subsequent binding and metabolism of human low-density lipoprotein. Biochem. J., 247, 79 - 84.
30. SEGLEN PO, GRINDE B AND SOLHEIM AE. (1979). Inhibition of the lysosomal pathway of protein degradation in isolated rat hepatocytes by ammonia, methylamine, chloroquine and leupeptin. Eur. J. Biochem., 95, 215 - 225.
31. SPETH PAJ, VAN HOESEL QGCM AND HAANEN C. (1988). Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokin., 15, 15-31.
32. TOKUI T, TOKUI Y, ISHIGAMI M, TANZAWA K, IKEDA T AND KOMAI T. (1994). Targeting of an antitumour agent, RS-1541 (palmiloyl-rhizoxin), via low-density lipoprotein receptor. Int. J. Pharmaceut., 110, 277 - 283.
33. TOMLINSON E. (1987). Theory and practice of site-specific drug delivery. Adv. Drug Del. Rev., 1, 87-198.
34. TRAIL PA, WILLNER D, LASCH SJ, HENDERSON AJ, HOFSTEAD S, CASAZZA AM, FIRESTONE RA, HELLSTRÖM I AND HELLSTRÖM KE. (1993). Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugatcs. Science, 261, 212 - 215.
35. VALLABHAJOSULA S, PAIDI M, BADIMON JJ, LE N-A, GOLDSMITH SJ, FUSTER V AND GINSBERG HN. (1988). Radiotracers for low density lipoprotein biodistribution studies in vivo: technetium-99m low density lipoprotein versus radioiodinated low density lipoprotein preparations. J. Nucl. Med., 29, 1237-1245.
36. VAN BERKEL ThJC, KRUIJT JK, VAN GENTT AND VAN TOL A. (1981). Saturable high affinity binding, uptake and degradation of rat plasma lipoproteins by isolated parenchymal and non-parenchymal cells from rat liver. Biochim. Biophys. Acta, 665, 22-33.
37. 2-macroglobulin recognition site. Biochem. J., 279, 863 - 870.
38. VITOLS SG, MASQUELIER M AND PETERSON CO. (1985). Selective uptake of a toxic lipophilic anthracycline derivative by the LDL receptor pathway in cultured fibroblasts. J. Med. Chem., 28, 451-454.
39. WEISGRABER KH AND MAHLEY RW. (1980). Subfractionation of human high density lipoproteins by heparin-Sepharose affinity chromatography. J. Lipid Res., 21, 316-325.
40. WEISGRABER KH, INNERARITY TL, AND MAHLEY RW. (1978). Role of the lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. J. Biol. Chem., 24, 9053-9062.